Immune checkpoint blockade therapies for HCC: current status and future implications

Abstract

Hepatocellular carcinoma (HCC) is the most lethal and common type of liver cancer with limited treatment options at the advanced stage. The use of immune checkpoint inhibitor (ICI) based immunotherapy is exponentially increasing in the treatment of patients with advanced solid tumors. The expression of immune checkpoints on tumor cells leading to lower activity of T-cells is one of the major mechanisms of immune escape. Checkpoint blockade immunotherapies with antibodies against PD-1, PD-L1 or CTLA-4 are being investigated in clinical trials in HCC patients. ICIs have improved survival in patients with inoperable advanced stage HCC where other curative treatments are not applicable. However, the response rates remain low with only a small subset of patients responding to this therapy. There is an unmet need to identify predictive markers to select those HCC patients who would benefit from ICI therapies. Importantly, epithelial-to-mesenchymal transition (EMT), a major process driving HCC invasion and metastasis by regulating the phenotypic cellular switching from epithelial to mesenchymal state, has been implicated as a resistance mechanism associated with ICI therapies. The role of EMT as a regulator of immune checkpoint molecule in HCC is just emerging. However, the consequence of EMT as a resistance mechanism in HCC patients undergoing ICI treatments remains unexplored. In this review, we summarize the recent clinical studies with ICIs in HCC and highlight the trials underway featuring novel monotherapies and combinatorial approaches based on immune and non-immune therapies. We will discuss the ongoing efforts to discover new immune checkpoint molecules in HCC as potential drug targets. We also highlight the role of EMT in facilitating therapy resistance in HCC treated with ICIs and discuss potential strategies to circumvent resistance in ICI treated HCC patients.

Keywords

Hepatocellular carcinoma / immunotherapy / immune checkpoint inhibitors / epithelial-to-mesenchymal transition / programmed cell death protein-1 / programmed death-ligand 1 / resistance

References

[1] Chacko S."Hepatocellular carcinoma: A life-threatening diseasen"..Biomed Pharmacother2016;84:1679-88

[2] Galun D,Bogdanovic A,Zuvela M.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies..J Hepatocell Carcinoma2017;4:93-103 PMCID:PMC5513853

[3] Tinkle CL.Hepatocellular carcinoma: natural history, current management, and emerging tools..Biologics2012;6:207-19 PMCID:PMC3421475

[4] Tian M,Liu W.Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention..Sci China Life Sci2019;

[5] Ueno M,Shigekawa Y,Hirono S.Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤ 5 cm: Cohort study based on serum HCC markers..J Hepatol2015;63:1352-9

[6] Buonaguro L,Cavalluzzo B,Tagliamonte M.Immunotherapy in hepatocellular carcinoma..Ann Hepatol2019;18:291-7

[7] Crocetti L,Cioni R.Loco-regional treatment of HCC: current status..Clin Radiol2017;72:626-35

[8] Llovet JM,Montaña X,Coll S.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[9] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[10] Mir N,Dhungel B,Steel JC.Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma..Curr Cancer Drug Targets2017;17:698-706

[11] Kudo M.Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond..World J Gastroenterol2019;25:789-807 PMCID:PMC6385008

[12] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma..N Engl J Med2018;379:54-63

[13] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[14] Kudo M.Systemic Therapy for Hepatocellular Carcinoma: Latest Advances..Cancers2018;10:412 PMCID:PMC6266463

[15] Zhu AX,Yen C-J,Galle PR.REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib..J Clin Oncol2018;36:4003

[16] Floudas CS,Greten TF.Immunotherapy: Current Status and Future Perspectives..Dig Dis Sci2019;64:1030-40

[17] Herbst RS,Kim DW,Pérez-Gracia JL.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial..Lancet2016;387:1540-50

[18] Hodi FS,McDermott DF,Sosman JA.Improved survival with ipilimumab in patients with metastatic melanoma..N Engl J Med2010;363:711-23 PMCID:PMC3549297

[19] Topalian SL,Pardoll DM.Immune checkpoint blockade: a common denominator approach to cancer therapy..Cancer Cell2015;27:450-61 PMCID:PMC4400238

[20] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[21] Siu EH,Chong CC,Lo KW.Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment..Transl Gastroenterol Hepatol2018;3:89 PMCID:PMC6286919

[22] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[23] Hato T,Greten TF,Zhu AX.Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions..Hepatology2014;60:1776-82 PMCID:PMC4211962

[24] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy..Nat Rev Cancer2012;12:252-64 PMCID:PMC4856023

[25] Shrestha R,Anaka M,Crawford DHG.Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma..Front Oncol2018;8:269 PMCID:PMC6053505

[26] Webb ES,Baleeiro R,Yuan M.Immune checkpoint inhibitors in cancer therapy..J Biomed Res2018;32:317-26 PMCID:PMC6163118

[27] Ardolino L.Immune checkpoint inhibitors in malignancy..Aust Prescr2019;42:62-7 PMCID:PMC6478962

[28] Okusaka T.Immunotherapy for hepatocellular carcinoma: current status and future perspectives..ESMO Open2018;3:e000455 PMCID:PMC6307608

[29] Pardee AD.Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities..Oncoimmunology2012;1:48-55 PMCID:PMC3376967

[30] Kapanadze T,Ma C,Zhao F.Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma..J Hepatol2013;59:1007-13 PMCID:PMC3805787

[31] Jenne CN.Immune surveillance by the liver..Nat Immunol2013;14:996-1006

[32] Okrah K,Liu B,Wagle MC.Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology..NPJ Precis Oncol2018;2:25 PMCID:PMC6237857

[33] Schneider H,Smith A,Rush C.Reversal of the TCR stop signal by CTLA-4..Science2006;313:1972-5

[34] Mizukoshi E,Arai K,Sakai A.Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma..Hepatology2011;53:1206-16

[35] Sangro B,de la Mata M,Garralda E.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C..J Hepatol2013;59:81-8

[36] Brar G,Brown ZJ.Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy..Therap Adv Gastroenterol2018;11:1756284818808086 PMCID:PMC6202741

[37] Iñarrairaegui M,Sangro B.Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes..Clin Cancer Res2018;24:1518-24

[38] Liu X.Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges..Oncologist2019;24:S3-S10 PMCID:PMC6394775

[39] Finn RS,Merle P,Bouattour M.Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)..J Clin Oncol2019;37:4004

[40] Busato D,Baboci L,Toffoli G.Novel immunotherapeutic approaches for hepatocellular carcinoma treatment..Expert Rev Clin Pharmacol2019;12:453-70

[41] Qin S,Kudo M,Vogel A.A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma..J Clin Oncol2018;36:TPS3110

[42] Huang J,Wu D,Ma L.Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors..J Clin Oncol2017;35:e15572

[43] Xu J,Jia R,Chang L.Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study..Clin Cancer Res2019;25:515-23

[44] Qin SK,Meng ZQ,Chai XL.LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment..Ann Oncol2018;29:mdy424.029

[45] Butte MJ,Phamduy TB,Freeman GJ.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses..Immunity2007;27:111-22 PMCID:PMC2707944

[46] Xu F,Zhu Y.Immune checkpoint therapy in liver cancer..J Exp Clin Cancer Res2018;37:110 PMCID:PMC5975687

[47] Calderaro J,Amaddeo G,Charpy C.Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features..Hepatology2016;64:2038-46

[48] Chang H,Kim A,Kim WB.Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma..APMIS2017;125:690-8

[49] Sideras K,Verheij J,Mancham S.PD-L1, Galectin-9 and CD8..Oncoimmunology2017;6:e1273309 PMCID:PMC5353918

[50] Wu K,Chen L,Welling TH.Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions..Cancer Res2009;69:8067-75 PMCID:PMC4397483

[51] Wainberg ZA,Jaeger D,Marshall J.Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)..J Clin Oncol2017;35:4071

[52] Nishida N.Immune checkpoint blockade for the treatment of human hepatocellular carcinoma..Hepatol Res2018;48:622-34

[53] Cella D,Escudier B,George S.Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial..Lancet Oncol2019;20:297-310 PMCID:PMC6701190

[54] Jain S.Ipilimumab for the treatment of melanoma..Melanoma Manag2015;2:33-9 PMCID:PMC6094709

[55] Kelley RK,Bendell JC,Borad MJ.Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses..J Clin Oncol2017;35:4073

[56] Abou-Alfa GK,Furuse J,Kelley RK.A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study..J Clin Oncol2018;36:TPS4144

[57] Finn RS,Qin S,Zhu AX.IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma..J Clin Oncol2018;36:TPS4141

[58] J Pishvaian M,Ryoo BY,Lee KH.LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC);.Ann Oncol2018;29:

[59] Ikeda M,Kudo M,Baron AD.A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)..J Clin Oncol2018;36:4076

[60] Xue JM,Zhong MX,Shen J.Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis..Onco Targets Ther2018;11:6119-28 PMCID:PMC6160267

[61] Deng L,Burnette B,Darga T.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice..J Clin Invest2014;124:687-95 PMCID:PMC3904601

[62] Kreidieh M,Shamseddine A.The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors..J Oncol2019;2019:4304817 PMCID:PMC6512065

[63] Harding JJ,Tan BR,Mody K.A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC)..J Clin Oncol2018;36:TPS4146

[64] Duffy AG,Makorova-Rusher O,Wedemeyer H.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma..J Hepatol2017;66:545-51 PMCID:PMC5316490

[65] Chang EWY,Koo S-L,Yeong JPS.A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: An immunological study of radioembolization in combination with anti-PD1 therapy in HCC..J Clin Oncol2018;36:TPS542

[66] Hecht JR,Pless M,Calvo A.A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318)..J Clin Oncol2018;36:TPS3105

[67] Jenkins RW,Flaherty KT.Mechanisms of resistance to immune checkpoint inhibitors..Br J Cancer2018;118:9-16 PMCID:PMC5765236

[68] Johnson DB,Compton ML,Gorham J.Fulminant Myocarditis with Combination Immune Checkpoint Blockade..N Engl J Med2016;375:1749-55 PMCID:PMC5247797

[69] Winer A,Borghaei H.Identifying and managing the adverse effects of immune checkpoint blockade..J Thorac Dis2018;10:S480-S9 PMCID:PMC5861268

[70] Puzanov I,Abdallah K,Brogdon C.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group..J Immunother Cancer2017;5:95 PMCID:PMC5697162

[71] McLoughlin KC,Shukla Y.Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary malignancies..Discov Med2018;26:85-92

[72] Koyama S,Li YY,Buczkowski KA.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints..Nat Commun2016;7:10501 PMCID:PMC4757784

[73] Peng W,Liu C,Creasy C.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy..Cancer Discov2016;6:202-16 PMCID:PMC4744499

[74] Gopalakrishnan V,Nezi L,Andrews MC.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients..Science2018;359:97-103 PMCID:PMC5827966

[75] Ma C,Heinrich B,Zhang Q.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells..Science2018;360:858 PMCID:PMC6407885

[76] Sul J,Jiang X,Keegan P.FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1..Oncologist2016;21:643-50 PMCID:PMC4861368

[77] Ma K,Wang M,Zhang Y.Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors..Expert Rev Mol Diagn2019;19:517-29

[78] Kalluri R.The basics of epithelial-mesenchymal transition..J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[79] Acloque H,Fishwick K,Nieto MA.Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease..J Clin Invest2009;119:1438-49 PMCID:PMC2689100

[80] Rao SR.Epithelial-to-mesenchymal transition as a potential target for antineoplastic therapies..J Cancer Clin Trials2016;1:e103

[81] Thiery JP,Huang RY.Epithelial-mesenchymal transitions in development and disease..Cell2009;139:871-90

[82] Jayachandran A,Dhungel B,Vasconcelos MYK.Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity..World J Stem Cells2017;9:159-68 PMCID:PMC5620425

[83] Gonzalez DM.Signaling mechanisms of the epithelial-mesenchymal transition..Sci Signal2014;7:re8 PMCID:PMC4372086

[84] Jayachandran A,Steel JC.Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma..J Hematol Oncol2016;9:74 PMCID:PMC5006452

[85] Singh M,Venugopal C.EMT: Mechanisms and therapeutic implications..Pharmacol Ther2018;182:80-94

[86] Kudo-Saito C,Takeuchi T.Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells..Cancer Cell2009;15:195-206

[87] Giannelli G,Dituri F.Role of epithelial to mesenchymal transition in hepatocellular carcinoma..J Hepatol2016;65:798-808

[88] Bertran E,Navarro E,Mainez J.Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta..Cell Signal2009;21:1595-606

[89] Bertran E,Sancho P,Lopez-Luque J.Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells..Hepatology2013;58:2032-44

[90] Wang B,Majumder S,Huang W.TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3..Oncogene2010;29:1787-97 PMCID:PMC2845743

[91] Wang MH,Zhou XM,Lu JB.Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway..Cell Death Dis2018;9:2 PMCID:PMC5849035

[92] Yamada S,Wei L,Fujii T.Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma..Ann Surg Oncol2014;21:3882-90

[93] Bouillez A,Jin C,Tagde A.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer..Oncogene2017;36:4037-46 PMCID:PMC5509481

[94] Terry S,Ortiz-Cuaran S,Saintigny P.New insights into the role of EMT in tumor immune escape..Mol Oncol2017;11:824-46 PMCID:PMC5496499

[95] Soundararajan R,Konen JM,Zhang X.Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy..Cancers2019;11:714 PMCID:PMC6562947

[96] Ye LY,Bai XL,Zhang Q.Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis..Cancer Res2016;76:818-30

[97] Mak MP,Diao L,Gibbons DL.A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition..Clin Cancer Res2016;22:609-20 PMCID:PMC4737991

[98] Lou Y,Cuentas ER,Chen L.Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma..Clin Cancer Res2016;22:3630-42 PMCID:PMC4947453

[99] Kim S,Kim MY,Go H.PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung..Hum Pathol2016;58:7-14

[100] Chen L,Goswami S,Ahn YH.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression..Nat Commun2014;5:5241 PMCID:PMC4212319

[101] David JM,McCampbell KK,Schlom J.A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells..Oncoimmunology2017;6:e1349589 PMCID:PMC5665067

[102] Chae YK,Ko T,Agte S.Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)..Sci Rep2018;8:2918 PMCID:PMC5811447

[103] Hirai M,Kobayashi Y,Bou-Gharios G.Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment..Int J Oncol2017;50:41-8 PMCID:PMC5182007

[104] Noman MZ,Abdou A,Terry S.The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200..Oncoimmunology2017;6:e1263412 PMCID:PMC5283623

[105] Chen L,Li J,Zhou Q.PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer..Cell Physiol Biochem2017;42:2267-80

[106] Funaki S,Kawamura T,Minami M.Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer..Oncol Rep2017;38:2277-84

[107] Wicklein D,Suling A,Lüers G.CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells..Sci Rep2018;8:11893 PMCID:PMC6082866

[108] Wang Y,Ye W,Ju H.EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells..Cell Cycle2018;17:1457-70 PMCID:PMC6132955

[109] Ueno T,Hatanaka KC,Mitsuhashi T.Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma..Oncotarget2018;9:20034-47 PMCID:PMC5929444

[110] Liang J,Zou Z,Zhou C.The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer..Sci Rep2018;8:6570 PMCID:PMC5919934

[111] Asgarova A,Godet Y,Nadaradjane A.PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma..Oncoimmunology2018;7:e1423170 PMCID:PMC5927541

[112] Li CW,Xia W,Chan LC.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity..Nat Commun2016;7:12632 PMCID:PMC5013604

[113] Ihling C,Zhang Y,Frick-Krieger E.Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma..Front Med2019;6:15 PMCID:PMC6375852

[114] Liakopoulou C,Vallianou NG.Silimarin and Cancer..Anticancer Agents Med Chem2018;18:1970-4

[115] Brown ZJ,Heinrich B,Fu Q.Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma..Cancer Immunol Immunother2018;67:1305-15 PMCID:PMC6085109

[116] Shali S,Zhang X,Jin Y.Ecto-5’-nucleotidase (CD73) is a potential target of hepatocellular carcinoma..J Cell Physiol2019;234:10248-59

[117] Yuan L,Yu G,Zhang L.Aberrant expression of B7-H4 may contribute to the development of hepatocellular carcinoma..Mol Med Rep2016;14:5015-24 PMCID:PMC5355751

[118] Teply BA.Identification and management of toxicities from immune checkpoint-blocking drugs..Oncology (Williston Park).2014;28 Suppl 3:30-8

[119] Signorelli D,Grazia G,Bertolini F.Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker..Biomed Res Int2019;2019:9056417 PMCID:PMC6507101

[120] Sharma P.Immune Checkpoint Therapy and the Search for Predictive Biomarkers..Cancer J2016;22:68-72 PMCID:PMC4847150

[121] Grosso J,Inzunza D,Simon JS.Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538)..J Clin Oncol2013;31:3016

[122] Rizvi NA,Snyder A,Makarov V.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[123] Dodagatta-Marri E,Reeves MQ,To MD.α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas..J Immunother Cancer2019;7:62 PMCID:PMC6399967

[124] Zheng B,Huang Y.Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3..Biochem Biophys Res Commun2018;495:1695-701